Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance and pharmacokinetics study of radiolabeled rogaratinib in healthy male volunteers
NL-OMON46572Completed
- Sponsor
- Bayer
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rogaratinib in Nonhematologic neoplasms, sponsored by Bayer. Primary endpoints: Mass balance and routes of excretion of total radioactivity, Plasma rogaratinib concentrations and 1 more. Started Apr 2018; status: completed.
02
Drugs
rogaratinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON46572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46572.